Renin-Angiotensin-Aldosterone System in Diabetes and Hypertension

Authors

  • Willa A. Hsueh MD,

    1. From the Diabetes Research Center, The Methodist Hospital Research Institute, Diabetes Research Center, Weill Cornell Medical College;
    Search for more papers by this author
  • Kathleen Wyne MD, PhD

    1. the Division of Diabetes, Obesity and Lipids, Department of Medicine, Weill Cornell Medical College, The Methodist Hospital, Houston, TX
    Search for more papers by this author

Willa A. Hsueh, MD, The Methodist Hospital Research Institute, Diabetes Research Center, Weill Cornell Medical College, 6565 Fannin Street, F7-070, Houston, TX 77030
E-mail: wahsueh@tmhs.org

Abstract

Activation of the renin-angiotensin-aldosterone system (RAAS) is the primary etiologic event in the development of hypertension in people with diabetes mellitus. Modulation of the RAAS has been shown to slow the progression and even cause regression of the microvascular and macrovascular complications associated with diabetes mellitus. Early pharmacotherapy with agents that decrease RAAS activation in the adipose tissue have had a dramatic impact on the prevalence of diabetes related complications. Recent data show that preventing the development of “angry fat” can prevent not just hypertension but also type 2 diabetes mellitus and its associated complications. This review updates what is known about angry fat and the role of RAAS inhibition in preventing the metabolic sequelae of local RAAS activation. J Clin Hypertens (Greenwich). 2011;13:224–237. © 2011 Wiley Periodicals, Inc.

Ancillary